Sanofi Pasteur, the vaccines division of Sanofi, has launched a vaccine research and development project targeting the prevention of Zika virus infection and disease.
With more than 130 biotech and 20 pharmaceutical companies currently developing immuno-oncology (I/O) therapies, the global oncology market could reach $40bn by 2020, says Tufts.
Crown Bioscience has announced the acquisition of PreClinOmics, an in vivo preclinical company specializing in early research in cardiovascular and metabolic diseases (CVMD).
Drugs currently being used to treat psychosis or depression may be able to treat emerging viruses, according to new research led by the University of Leeds.
Bial says BIA 10-2474 met safety and tolerability requirements for human trials, but the firm cannot rule the drug out as the cause of lesions in dogs in a preclinical study.
Anapath has seen a surge in histotechnology services from Europe pharma and rival CROs as consolidation in the preclinical sector has left a lack of capacity for such work.
Juno Therapeutics and Fred Hutchinson Cancer Research Center (Fred Hutch) have announced the creation of a new clinical trials unit (CTU) dedicated to immuno-oncology.
Ennaid Therapeutics has announced it is developing therapeutic cures to help those that may become infected with the Zika Virus, and it may be available in less than four years.
Zika researchers are using animal models and epidemiological studies to try and determine if the virus causes birth defects and neurological disorders.
Researchers have created the first robotically driven experimentation system which reduces the number of necessary experiments throughout drug discovery by 70%.
Crown Bioscience has expanded its portfolio of non-animal based disease models by licensing a range of cellular prostate cancer models developed by UK academics.
Repositive has secured funding to develop a premium version of its gene data collaboration platform for personalised medicine and rare disease researchers.
Certara’s new consulting firm will rely on modeling and simulation expertise to expedite the drug development process, as China commits to increasing innovation.
Pfizer has invested $46m in separate collaborations with four R&D companies specialising in developing ADCs, immuno-oncology candidates and gene-therapies.
Newly private WuXi AppTec has announced plans to invest $120m in a biopharmaceutical development laboratory and clinical-scale manufacturing facility in Shanghai, China.
Charles River is set to acquire WIL Research for approximately $585 million in cash, further enhancing the company’s capabilities to include contract development and manufacturing (CDMO).
AMRI has opened a drug discovery center, citing growing customer demand for biology, high-throughput screening, in vitro pharmacology, and medicinal chemistry at a single site.
An Israeli researcher says a cost-effective method for making human liver cells offers drug developers better safety evaluation and will “undoubtedly” replace animal testing.
New acquisition Sigma Aldrich will play a part in African growth plans in addition to giving it a presence in the preclinical services sector says Merck*.
Preclinical CRO Biopta will add stem cell programming tech to its offering, expand in Japan and nearly double its workforce under new owner, Reprocell.
Cyprotex has expanded its toxicology offering with a new in silico technology it claims will reduce preclinical costs and cut the number of animal studies required.
Charles River has reported strong Q3 sales despite weakness in Japan and plans to grab space in emerging early discovery, bio-testing and Chinese markets.
Covance has reported capacity use at its preclinical toxicology business is in the 70% range, meaning it is still well below optimal levels despite recent improvements.
CRO SNBL USA, daughter company of Shin Nippon, has won a BARDA contract for animal models to treat injuries from chemical, radiological and nuclear attack.
An expanded San Diego facility will support demand for preclinical and clinical development services driven by the growth in the antibody and biosimilar sector, Intertek says.
A UK firm has launched a searchable database of genomic data from sources all over the world that it says will accelerate development of personalised medicines.
Demand for biopharmaceutical testing is in part responsible for higher capacity utilisation but, despite encouraging signs, it is too early to say if preclinical pricing will improve accordingly says Envigo.
